[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054288":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":16,"studyPopulation":29,"armGroups":16,"interventions":16,"overallOfficials":16,"centralContacts":30,"locations":40,"responsibleParty":76,"collaborators":16,"id":78,"slug":16,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":16,"enrollmentInfo":86,"targetDuration":16,"studyType":89,"phases":16,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":68,"whyStopped":16,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Parameters obtained using the Patlak Direct IDIF reconstruction method, Ki mean, Ki max, DV mean and DV max (standards) in FDG-PET LAFOV in the residual disease and post-treatment inflammation groups","The reference test for the diagnosis of \" residual diseases \" and \" post-radiation inflammation\" will be based on the conclusion of the multidisciplinary team meeting ruling on the results of composite data, including clinical examination, pathological examination, morphological imaging (CT or MRI) and\u002For functional imaging (early evaluation PET).\n\nThe index test will be based on FDG-PET LAFOV whose parameters obtained using the Patlak Direct IDIF, Ki mean, Ki max, DV mean and DV max (standards) in the residual disease and post-therapy inflammation groups.","3 months post-curative radiotherapy",[14,17,19,21,23],{"measure":15,"description":16,"timeFrame":12},"Standard Ki and DV parameters in LAFOV FDG-PET and anatomical pathology characteristics of tumours (p16 status, CPS, degree of tumour differentiation).",null,{"measure":18,"description":16,"timeFrame":12},"Dynamic (standard Ki and DV) and static (SUVmax, SUVmean, SUVpeak, MTV, TLG, textural features) parameters in LAFOV FDG-PET.",{"measure":20,"description":16,"timeFrame":12},"Ki and DV parameters in LAFOV FDG-PET and the occurrence of post-radiation toxicity",{"measure":22,"description":16,"timeFrame":12},"DV and Ki parameters derived from direct and indirect Patlak reconstructions with IDIF and\u002For PBIF.",{"measure":24,"description":16,"timeFrame":25},"Dates of imaging, dates of progression, dates of death and end of study dates","12 months post TEP-FDG LAVOF imaging",{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":27,"timePerspective":28,"maskingInfo":16},"COHORT","PROSPECTIVE","Patients treated with radiotherapy for curative purposes for squamous cell carcinoma of the upper aerodigestive tract.",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":16,"email":35},"Ronan ABGRAL, Pr","CONTACT","+332 98 22 30 69","ronan.abgral@chu-brest.fr",{"name":37,"role":33,"phone":38,"phoneExt":16,"email":39},"Jean-Christophe LECLERE, Dr","+332 98 22 02 91","jean-christophe.leclere@chu-brest.fr",[41,59,66],{"facility":42,"status":43,"city":44,"state":16,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Centre finistérien de radiothérapie et d'oncologie - site Clinique Pasteur","NOT_YET_RECRUITING","Brest","29200","France","FR",{"type":49,"coordinates":50},"Point",[51,52],-4.48628,48.39029,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":57,"phoneExt":16,"email":58},"Mohammed BOUCHEKOUA","+332 22 90 02 45","mbouchekoua@oncologie-brest.fr",{"facility":60,"status":43,"city":44,"state":16,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Centre finistérien de radiothérapie et d'oncologie - Site de l'hôpital La Cavale Blanche",{"type":49,"coordinates":62},[51,52],{"lat":52,"lon":51},[65],{"name":56,"role":33,"phone":57,"phoneExt":16,"email":58},{"facility":67,"status":68,"city":44,"state":16,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"CHU Brest","RECRUITING",{"type":49,"coordinates":70},[51,52],{"lat":52,"lon":51},[73],{"name":74,"role":33,"phone":75,"phoneExt":16,"email":39},"Jean-Christophe Leclere, Dr","+33229020291",{"type":77,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100054288",false,"NCT07417605","Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.","POLARIS","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Presenting with head and neck squamous cell carcinoma\n* Completed curative treatment with external radiation therapy\n* Eligible for dynamic LAFOV FDG-PET scan for therapeutic evaluation at 3 months\n* Having given consent for the end-of-treatment consultation\n\nExclusion Criteria:\n\n* Hypersensitivity to 18F-FDG or other excipients contained in the contrast agent\n* Pregnancy or breastfeeding\n* History of treated upper gastrointestinal tract cancer\n* Other histology\n* Incomplete RTE treatment regimen\n* Refusal to participate","ALL","18 Years",{"count":87,"type":88},180,"ESTIMATED","OBSERVATIONAL","This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.",[92],"Head & Neck Squamous Cell Carcinoma",[94,95,96,97],"4D dynamic analysis","post-radical inflammation","squamous cell carcinomas","FDG-PET LAFOV","2026-07-10",{"date":100,"type":101},"2026-07-13","ACTUAL",{"date":103,"type":101},"2026-04-13",{"date":105,"type":88},"2029-06-13",{"name":5,"class":6},3]